| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC | Chief Scientific Officer | Option to purchase Ordinary Shares | 1,074,696 | 20 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 20 Feb 2025 | 2 | $0 | 4 | Chief Scientific Officer | 20 Feb 2025, 17:34 |
| ADAP | Adaptimmune Therapeutics PLC | 15 Jan 2024 | 2 | $0 | 4 | Chief Scientific Officer | 17 Jan 2024, 17:02 |
| ADAP | Adaptimmune Therapeutics PLC | 17 Jan 2023 | 3 | $0 | 4 | Chief Scientific Officer | 17 Jan 2023, 20:05 |
| ADAP | Adaptimmune Therapeutics PLC | 04 May 2022 | 2 | $0 | 4 | Chief Scientific Officer | 04 May 2022, 21:03 |
| ADAP | Adaptimmune Therapeutics PLC | 04 May 2022 | 0 | $0 | 3 | Chief Scientific Officer | 04 May 2022, 21:01 |